MCID: MLG053
MIFTS: 38

Malignant Ovarian Brenner Tumor malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Malignant Ovarian Brenner Tumor

Aliases & Descriptions for Malignant Ovarian Brenner Tumor:

Name: Malignant Ovarian Brenner Tumor 12 14
Malignant Brenner Tumor 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4217
MeSH 42 D001948
NCIt 47 C4270
SNOMED-CT 64 42194009
UMLS 69 C0334495

Summaries for Malignant Ovarian Brenner Tumor

Disease Ontology : 12 A malignant ovarian surface epithelial-stromal neoplasm that has material basis in the surface epithelium of the ovary.

MalaCards based summary : Malignant Ovarian Brenner Tumor, also known as malignant brenner tumor, is related to bartholin's gland adenomyoma and eccrine sweat gland neoplasm. An important gene associated with Malignant Ovarian Brenner Tumor is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and PI3K-Akt signaling pathway. The drugs Bevacizumab and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Malignant Ovarian Brenner Tumor

Diseases in the Ovarian Brenner Tumor family:

Malignant Ovarian Brenner Tumor

Diseases related to Malignant Ovarian Brenner Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
id Related Disease Score Top Affiliating Genes
1 bartholin's gland adenomyoma 10.3 TP53 WT1
2 eccrine sweat gland neoplasm 10.3 BRCA1 THBD WT1
3 pneumonia 10.3 BRCA1 PTHLH WT1
4 spastic paraplegia 1 10.2 PIK3CA TERT TP53
5 chondroblastoma 10.2 KRT20 THBD WT1
6 breast pericanalicular fibroadenoma 10.2 BRCA1 KRT20 TP53
7 tumor of exocrine pancreas 10.2 KRT20 THBD WT1
8 gallbladder pleomorphic giant cell adenocarcinoma 10.2 HRAS TP53 WT1
9 breast ductal carcinoma 10.2 KRAS TP53 WT1
10 nemaline myopathy 8, autosomal recessive 10.2 BRCA1 KRAS PIK3CA
11 adult syndrome 10.2 KRAS PIK3CA TP53
12 microglandular adenosis 10.2 KRT7 UPK3A
13 melanocytic nevus syndrome, congenital, somatic 10.2 HRAS KRAS PIK3CA
14 spastic ataxia 5 10.2 KRT20 PAX8 TP53
15 kidney clear cell sarcoma 10.2 HRAS KRAS PIK3CA
16 familial hyperaldosteronism 10.2 HRAS KRAS WT1
17 brown-vialetto-van laere syndrome 10.2 KRT20 TP53 WT1
18 papillary transitional carcinoma 10.2 KRT20 TP53 UPK3A
19 spongiotic dermatitis 10.2 HRAS KRAS PIK3CA
20 vascular hemostatic disease 10.2 HRAS KRAS PIK3CA
21 ossifying fibromyxoid tumor 10.2 HRAS KRAS TP53
22 aicardi-goutieres syndrome 10.2 HRAS KRAS TP53
23 arthus reaction 10.2 HRAS KRAS TP53
24 benign ependymoma 10.2 KRAS PTHLH TP53
25 giant cell tumor 10.2 KRAS KRT20 TP53
26 postpartum depression 10.2 BRCA1 SMUG1 TP53
27 kimura disease 10.2 KRT7 PAX8
28 pelvic inflammatory disease 10.2 HRAS KRAS KRT20
29 uterine disease 10.1 PIK3CA SMUG1 TP53
30 brachial plexus neuropathy 10.1 HRAS KRAS TP53
31 radiculopathy 10.1 KRT20 KRT7
32 larynx liposarcoma 10.1 BRCA1 MLH1 TP53
33 adult myxoid chondrosarcoma 10.1 KRT20 KRT7
34 retroperitoneal neuroblastoma 10.1 KRAS PIK3CA PTHLH TP53
35 extra-adrenal pheochromocytoma 10.1 KRAS PAX8 TP53 WT1
36 pancreatic cystadenoma 10.1 KRAS PIK3CA PTHLH TP53
37 rhinitis 10.1 KRT20 PAX8 PTHLH TP53
38 gestational choriocarcinoma 10.1 SMUG1 TP53 WT1
39 inhibited male orgasm 10.1 KRAS SMUG1 TP53
40 klatskin's tumor 10.1 KRT20 KRT7 UPK3A
41 reticulosarcoma 10.1 GATA3 SMUG1 TP53
42 gastrointestinal neuroendocrine tumor 10.1 KRT7 PAX8
43 angiolipomatosis, familial 10.1 KRT20 KRT7 UPK3A
44 meninges hemangiopericytoma 10.1 KRAS KRT20 PAX8 WT1
45 nodular tenosynovitis 10.1 KRT7 PAX8 WT1
46 bronchus mucoepidermoid carcinoma 10.1 KRT20 KRT7
47 skin papilloma 10.1 HRAS KRT20 MLH1
48 suppurative lymphadenitis 10.1 GATA3 KRT7
49 malignant mediastinal neurogenic neoplasm 10.1 CEACAM5 TP53
50 gonococcal seminal vesiculitis 10.1 HRAS KRAS SMUG1

Graphical network of the top 20 diseases related to Malignant Ovarian Brenner Tumor:



Diseases related to Malignant Ovarian Brenner Tumor

Symptoms & Phenotypes for Malignant Ovarian Brenner Tumor

MGI Mouse Phenotypes related to Malignant Ovarian Brenner Tumor:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 BRCA1 GATA3 KRAS KRT7 MLH1 PAX8
2 homeostasis/metabolism MP:0005376 10.37 BRCA1 GATA3 HRAS KRAS KRT7 MLH1
3 mortality/aging MP:0010768 10.3 BRCA1 GATA3 HRAS KRAS MLH1 PAX8
4 cardiovascular system MP:0005385 10.27 BRCA1 GATA3 HRAS KRAS PAX8 PIK3CA
5 endocrine/exocrine gland MP:0005379 10.26 BRCA1 GATA3 HRAS KRAS MLH1 PAX8
6 growth/size/body region MP:0005378 10.25 BRCA1 GATA3 HRAS KRAS PAX8 PIK3CA
7 digestive/alimentary MP:0005381 10.15 THBD TP53 BRCA1 GATA3 KRAS MLH1
8 embryo MP:0005380 10.14 BRCA1 GATA3 KRAS PAX8 PIK3CA THBD
9 integument MP:0010771 10.13 BRCA1 GATA3 HRAS KRAS MLH1 PIK3CA
10 nervous system MP:0003631 10.1 PAX8 PIK3CA PTHLH TERT THBD TP53
11 neoplasm MP:0002006 10.09 BRCA1 HRAS KRAS MLH1 PIK3CA SMUG1
12 renal/urinary system MP:0005367 10 PTHLH THBD TP53 UPK3A WT1 BRCA1
13 normal MP:0002873 9.97 BRCA1 GATA3 HRAS KRAS PAX8 TERT
14 no phenotypic analysis MP:0003012 9.91 GATA3 HRAS KRAS PAX8 PIK3CA TP53
15 reproductive system MP:0005389 9.9 BRCA1 GATA3 KRAS MLH1 PAX8 PIK3CA
16 respiratory system MP:0005388 9.61 BRCA1 HRAS KRAS MLH1 PTHLH TERT
17 skeleton MP:0005390 9.28 TERT TP53 BRCA1 GATA3 HRAS KRAS

Drugs & Therapeutics for Malignant Ovarian Brenner Tumor

Drugs for Malignant Ovarian Brenner Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
5
Succinylcholine Approved Phase 3 306-40-1 5314
6 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
7 Angiogenesis Inhibitors Phase 3
8 Angiogenesis Modulating Agents Phase 3
9 Antibodies Phase 3,Phase 1
10 Antibodies, Monoclonal Phase 3,Phase 1
11 Antimitotic Agents Phase 3,Phase 1
12 Antineoplastic Agents, Phytogenic Phase 3,Phase 1
13 Endothelial Growth Factors Phase 3
14 Immunoglobulin G Phase 3
15 Immunoglobulins Phase 3,Phase 1
16 Mitogens Phase 3
17 Carotenoids Phase 3
18 Micronutrients Phase 3
19 Trace Elements Phase 3
20 Neuromuscular Agents Phase 3
21 Neuromuscular Blocking Agents Phase 3
22 Neuromuscular Depolarizing Agents Phase 3
23 Peripheral Nervous System Agents Phase 3
24
Metformin Approved Phase 2 657-24-9 14219 4091
25
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
26 Imatinib Mesylate Phase 2 123596
27 Protein Kinase Inhibitors Phase 2
28
Iodine Phase 1, Phase 2 7553-56-2 807
29 Hypoglycemic Agents Phase 2
30
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
31
nivolumab Approved Phase 1 946414-94-4
32
Doxil Approved June 1999 Phase 1 31703
33 Anti-Bacterial Agents Phase 1
34 Antibiotics, Antitubercular Phase 1
35 Topoisomerase Inhibitors Phase 1
36 Immunotoxins Phase 1
37 Glutamic Acid Nutraceutical Phase 1
38
Formaldehyde Approved, Vet_approved 50-00-0 712
39 CHI3L1 protein, human
40 Cola Nutraceutical

Interventional clinical trials:

(show all 19)
id Name Status NCT ID Phase
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
2 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
4 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
5 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
6 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
7 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
8 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
9 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2
10 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1
11 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1
12 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1
13 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
14 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
15 Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers Recruiting NCT02526017 Phase 1
16 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
17 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514
18 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Active, not recruiting NCT00899093
19 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Active, not recruiting NCT01080521

Search NIH Clinical Center for Malignant Ovarian Brenner Tumor

Genetic Tests for Malignant Ovarian Brenner Tumor

Anatomical Context for Malignant Ovarian Brenner Tumor

MalaCards organs/tissues related to Malignant Ovarian Brenner Tumor:

39
Ovary

Publications for Malignant Ovarian Brenner Tumor

Articles related to Malignant Ovarian Brenner Tumor:

id Title Authors Year
1
Malignant ovarian Brenner tumor. A case report evaluated with (18)F-FDG PET/CT. ( 25890890 )
2015
2
The histologic features and histogenesis of malignant ovarian Brenner tumor. ( 3100186 )
1986

Variations for Malignant Ovarian Brenner Tumor

Expression for Malignant Ovarian Brenner Tumor

Search GEO for disease gene expression data for Malignant Ovarian Brenner Tumor.

Pathways for Malignant Ovarian Brenner Tumor

Pathways related to Malignant Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 CEACAM5 GATA3 HRAS KRAS PIK3CA THBD
2 12.52 BRCA1 HRAS KRAS PIK3CA TP53
3 12.48 HRAS KRAS MLH1 PAX8 PIK3CA TP53
4 12.43 BRCA1 HRAS KRAS PIK3CA TP53
5
Show member pathways
12.39 HRAS KRAS PIK3CA TP53
6
Show member pathways
12.37 GATA3 HRAS KRAS PIK3CA
7
Show member pathways
12.34 BRCA1 HRAS KRAS PIK3CA
8
Show member pathways
12.33 GATA3 HRAS PIK3CA TP53
9 12.3 HRAS KRAS PIK3CA TERT TP53
10
Show member pathways
12.25 HRAS KRAS PIK3CA TP53
11 12.23 HRAS KRAS PIK3CA TP53
12 12.22 HRAS KRAS PIK3CA TP53
13
Show member pathways
12.18 HRAS KRAS MLH1 PIK3CA TP53
14
Show member pathways
12.12 HRAS KRAS PIK3CA TP53
15
Show member pathways
12.1 HRAS KRAS PIK3CA ZMYM2
16
Show member pathways
12.08 HRAS KRAS PIK3CA TP53
17 12.04 HRAS KRAS PIK3CA TP53
18
Show member pathways
12.02 HRAS KRAS PIK3CA TP53
19 11.99 HRAS KRAS PIK3CA TP53
20 11.92 HRAS KRAS PIK3CA TP53
21
Show member pathways
11.91 CEACAM5 HRAS KRAS PIK3CA THBD
22 11.9 HRAS KRAS PIK3CA TP53
23 11.87 HRAS KRAS PIK3CA TP53
24
Show member pathways
11.82 HRAS KRAS PIK3CA
25 11.79 HRAS KRAS PIK3CA
26 11.77 HRAS KRAS PIK3CA THBD
27
Show member pathways
11.75 HRAS KRAS PIK3CA
28
Show member pathways
11.72 HRAS KRAS PIK3CA ZMYM2
29 11.65 HRAS PAX8 PIK3CA
30 11.62 HRAS KRAS TP53
31 11.53 HRAS KRAS TP53 UPK3A
32 11.49 BRCA1 MLH1 PIK3CA TP53
33 11.28 BRCA1 HRAS PIK3CA TP53
34 11.27 HRAS KRAS TP53
35 11.18 HRAS KRAS PIK3CA
36
Show member pathways
11.16 HRAS PIK3CA TERT
37 11.07 HRAS KRAS PIK3CA TP53
38 10.79 HRAS KRAS
39 10.39 HRAS KRAS PAX8 TP53

GO Terms for Malignant Ovarian Brenner Tumor

Cellular components related to Malignant Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 TERT TP53 ZMYM2

Biological processes related to Malignant Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.89 GATA3 HRAS PTHLH TP53 WT1
2 axon guidance GO:0007411 9.78 GATA3 HRAS KRAS PIK3CA
3 female pregnancy GO:0007565 9.77 KRAS PTHLH THBD
4 positive regulation of gene expression GO:0010628 9.77 BRCA1 GATA3 HRAS KRAS TP53
5 Ras protein signal transduction GO:0007265 9.72 HRAS KRAS TP53
6 epidermal growth factor receptor signaling pathway GO:0007173 9.63 HRAS KRAS PIK3CA
7 mesonephros development GO:0001823 9.58 GATA3 PAX8
8 replicative senescence GO:0090399 9.58 TERT TP53
9 response to isolation stress GO:0035900 9.57 HRAS KRAS
10 mesenchymal to epithelial transition GO:0060231 9.56 GATA3 WT1
11 negative regulation of neuron apoptotic process GO:0043524 9.56 HRAS KRAS PIK3CA TERT
12 cellular response to gonadotropin stimulus GO:0071371 9.54 PAX8 WT1
13 otic vesicle development GO:0071599 9.52 GATA3 PAX8
14 positive regulation of histone H3-K9 acetylation GO:2000617 9.51 BRCA1 GATA3
15 ERBB2 signaling pathway GO:0038128 9.5 HRAS KRAS PIK3CA
16 metanephric S-shaped body morphogenesis GO:0072284 9.43 PAX8 WT1
17 metanephric epithelium development GO:0072207 9.4 PAX8 WT1
18 kidney development GO:0001822 9.26 GATA3 PAX8 UPK3A WT1
19 positive regulation of thyroid hormone generation GO:2000611 9.16 GATA3 PAX8
20 leukocyte migration GO:0050900 9.02 CEACAM5 HRAS KRAS PIK3CA THBD

Molecular functions related to Malignant Ovarian Brenner Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.86 BRCA1 GATA3 HRAS KRAS KRT20 KRT7
2 transcription regulatory region DNA binding GO:0044212 9.02 BRCA1 GATA3 PAX8 TP53 WT1

Sources for Malignant Ovarian Brenner Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....